R&D News | pharmaphorum

News

AZ trumpets Farxiga survival data in renal disease at ESC 20...

AstraZeneca’s Farxiga is already ahead of rivals in the SGLT2 inhibitor field in heart failure, and now looks set to repeat that success in renal disease after reporting stella

News

The diagnosis Hepatitis written on a clipboard

Ionis deal delivers for GSK as HBV drug hits the mark in pha...

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widesprea

News

Phase 3 wins put Dermavant closer to filing Otezla rival tap...

Just two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could be a few months away from filing for approval of

News

Moderna’s COVID vaccine works in older people, according to ...

Moderna has said that its coronavirus vaccine stimulated an immune response in older people in phase 1 trials, suggesting that the jab is effective in the age groups most susceptible to COVID-19

News

Chasing Regeneron, AZ starts trials of its COVID-19 antibody...

The first patients have been dosed in a trial of two AstraZeneca antibodies, collectively known as AZD7442, that are being developed to both treat and prevent coronavirus infec

News

Blow for Novartis as PD-1 drug spartalizumab flunks trial

Novartis’ hopes of catching up with other companies in immuno-oncology have been dented after PD-1 inhibitor spartalizumab failed a phase 3 trial in skin cancer.

AZ trumpets Farxiga survival data in renal disease at ESC 20...

Ionis deal delivers for GSK as HBV drug hits the mark in pha...

Phase 3 wins put Dermavant closer to filing Otezla rival tap...

Moderna’s COVID vaccine works in older people, according to ...

Chasing Regeneron, AZ starts trials of its COVID-19 antibody...

Blow for Novartis as PD-1 drug spartalizumab flunks trial

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks